The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Two major highlights from ASH for patients with relapsed/refractory multiple myeloma
Featured:
Miles PrinceThe Multiple Myeloma Hub are pleased to present a series of expert interviews from the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this video, Miles Prince, Peter MacCallum Cancer Centre, Melbourne, AU, presents two major highlights from ASH for patients with relapsed/refractory multiple myeloma.
Miles Prince talks about the key topics that have been presented in ASH 2019. He describes the key principles of CAR T therapy in myeloma, and discusses the emerging CAR T therapies around the world, and the efficacy of CAR T in different patient populations. Miles Prince concludes by summarizing the results of studies that examined monoclonal antibodies in both the transplant eligible and ineligible setting.
Two major highlights from ASH for patients with relapsed/refractory multiple myeloma